pharmexec.com /1 month ago

<![CDATA[Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreeme...

Read source
medcitynews.com /4 weeks ago

Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition

Alcon’s Neurotech Pharmaceuticals acquisition brings the rare vision disorder cell therapy Encelto as well as the platform technology that developed it. Last year, Alcon acquired a...

Read source
orthospinenews.com /5 days ago

NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates

MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) — NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative…

Read source
biopharmadive.com /1 month ago

Optogenics researchers win a Nobel Prize; Roche bets on Alector brain drug

The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the FDA endorsed broader us...

Read source
biopharmadive.com /1 month ago

Rapport’s epilepsy drug finds surprising success in bipolar trial

Despite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results that could help it tap a billion-dollar-plus market oppor...

Read source
asia.nikkei.com /3 weeks ago

Takeda debuts narcolepsy drug targeting root cause, capping 15-year effort

Read source
cafepharma.com /6 days ago

Axonics

Axonics Anonymous (not verified) Mon, 11/16/2026 - 00:40 field_thread_url https://cafepharma.com/boards/threads/axonics.704805/ board na...

Read source
newswire.com /2 weeks ago

DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee

Corexa Pharmacy to dispense compounded BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax in accordance with HHS' recently updated Enforcement Discretion PolicyBulk drug substance ac...

Read source
seekingalpha.com /2 weeks ago

Neuronetics, Inc. (STIM) Q3 2026 Earnings Call Transcript

Read source
seekingalpha.com /1 week ago

NeuroPace, Inc. (NPCE) Q3 2026 Earnings Call Transcript

Read source
wired.com /1 month ago

A New Neurotech Startup Launches to Rival Sam Altman’s Merge Labs

Bridge Neurotech is planning to build a wearable brain-computer interface that uses ultrasound.

Read source
orthospinenews.com /1 week ago

Pasithea Therapeutics Reports Positive Early Trial Results for PAS-004 in Neurofibromatosis

MIAMI, Nov. 13, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage…

Read source
biopharmadive.com /1 month ago

A Takeda spinout builds case for its Parkinson’s drug

Cerevance plans to meet with the FDA to “determine next steps” for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.

Read source
investing.com /1 month ago

SpyGlass Pharma reports 4-year glaucoma implant trial results

Read source
newswire.com /1 month ago

NexTel Medical Corp. Announces Next-Generation Wellness Product Line Incorporating FDA-Approved Pharmaceuticals

Innovative Delivery Technologies Aimed at Enhancing Bioavailability and Expanding Patient Access Beyond Traditional Injections

Read source
prweb.com /1 week ago

Neuvivo appoints Michael McGrath MD, PhD as Chief Executive Officer

Appointment follows 12-month interim tenure of scientific, regulatory and commercial achievements for Phase 3 trial preparation in ALS PALO ALTO, Calif., Nov. 13, 2026 /PRNewswire-...

Read source
biopharmadive.com /1 week ago

London biotech Oyster harvests $60M for tau-targeting brain drugs

Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.

Read source
biopharmadive.com /1 month ago

Parkinson’s cell therapy developer files to go public

Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.

Read source
orthotw.com /1 month ago

Consano Bio Raises More Than $15 Million in Oversubscribed Financing to Advance C-1101 in Chronic Painful Lumbosacral Ra...

Proceeds will fund completion of the Phase 1 trial and continued development of C-1101, a potential first-in-class disease-modifying therapeutic -- Clinical data expected in 1H 202...

Read source
newswire.com /1 month ago

Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA

~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~

Read source
biopharmadive.com /1 week ago

This week in charts: Brain drugs are back on venture capitalists’ minds

Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.

Read source
cafepharma.com /2 weeks ago

Priovant

Priovant Anonymous (not verified) Fri, 11/06/2026 - 18:33 field_thread_url https://cafepharma.com/boards/threads/priovant.718186/ board...

Read source
pharmexec.com /3 weeks ago

<![CDATA[Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Frag...

Read source
orthotw.com /1 week ago

NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury

Breakthrough Therapy designation granted based on FDA’s review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI study.

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.